Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.85 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.85 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.85 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.85 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.71 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.67 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.65 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.65 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL29801499 | 0.95 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL28065954 | 0.95 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL30094506 | 0.95 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL76681 | 0.95 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL376208 | 0.95 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL157643 | 0.95 | SLC28A1 (0.90) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL28280241 | 0.94 | SLC28A1 (0.83) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL17074124 | 0.94 | SLC28A1 (0.88) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL2370972 | 0.94 | SLC28A1 (0.88) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Uridine SCHEMBL28131489 | 0.94 | SLC28A1 (0.88) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223538-B2 | Post-synthesis labeling of nucleic acids, assays using nucleic acids that are labeled post-synthetically, single nucleotide polymorphism detection, and associated compounds and microarrays | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2007-05-29 | — | — | US | claimed |
| CN-1620515-A | Post-synthesis labeling of nucleic acids and uses thereof | AMERSHAM BIOSCIENCES AB (SE) | 2005-05-25 | — | — | CN | claimed |
| EP-1461455-A2 | POST-SYNTHESIS LABELING OF NUCLEIC ACIDS AND USES THEREOF | Amersham Biosciences AB (SE) | 2004-09-29 | — | — | EP | claimed |
| WO-2003052115-A2 | POST-SYNTHESIS LABELING OF NUCLEIC ACIDS AND USES THEREOF | AMERSHAM BIOSCIENCES AB (SE) | 2003-06-26 | — | — | WO | claimed |
| US-20030119005-A1 | Post-synthesis labeling of nucleic acids, assays using nucleic acids that are labeled post-synthetically, single nucleotide polymorphism detection, and associated compounds and microarrays | MOTOROLA, INC. | 2003-06-26 | — | — | US | claimed |
| CN-116171160-A | Compositions and methods for treating metabolic syndrome | 戴瑟纳制药公司 | 2023-05-26 | — | — | CN | disclosed |
| US-20230122244-A1 | CHIRALLY-ENRICHED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2023-04-20 | — | — | US | disclosed |
| US-11597932-B2 | Chirally-enriched double-stranded RNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210207144-A1 | CHIRALLY-ENRICHED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2021-07-08 | — | — | US | disclosed |
| EP-2380897-B1 | RNAi modulation of ApoB and uses thereof | ALNYLAM PHARMACEUTICALS INC (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2377873-B1 | RNAi modulation of ApoB and uses thereof | ALNYLAM PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| CN-101133074-A | RNAi modulation of APOB and uses thereof | ALNYLAM PHARMACEUTICALS INC (US) | 2008-02-27 | — | — | CN | disclosed |
| US-7223538-B2 | Post-synthesis labeling of nucleic acids, assays using nucleic acids that are labeled post-synthetically, single nucleotide polymorphism detection, and associated compounds and microarrays | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2007-05-29 | — | — | US | disclosed |
| CN-1620515-A | Post-synthesis labeling of nucleic acids and uses thereof | AMERSHAM BIOSCIENCES AB (SE) | 2005-05-25 | — | — | CN | disclosed |
| EP-1461455-A2 | POST-SYNTHESIS LABELING OF NUCLEIC ACIDS AND USES THEREOF | Amersham Biosciences AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003052115-A2 | POST-SYNTHESIS LABELING OF NUCLEIC ACIDS AND USES THEREOF | AMERSHAM BIOSCIENCES AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| US-20030119005-A1 | Post-synthesis labeling of nucleic acids, assays using nucleic acids that are labeled post-synthetically, single nucleotide polymorphism detection, and associated compounds and microarrays | MOTOROLA, INC. | 2003-06-26 | — | — | US | disclosed |